|Bid||0.0300 x N/A|
|Ask||0.1000 x N/A|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics on their latest news.
VANCOUVER, BC / ACCESSWIRE / May 30, 2022 / The Power Play by The Market Herald has announced the release of a new interview with GeneTether Therapeutics on their latest news.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.
GeneTether Therapeutics Inc., ("GeneTether" or the "Company") (CSE: GTTX) announced today that the United States Patent and Trademark Office has granted patent #11,339,385 entitled "Modified Nucleic Acid Editing Systems for Tethering Donor DNA" related to its GeneTether platform technology. The claims cover a composition of matter for tethering a donor DNA template to a fusion protein of a nuclease and the lac repressor DNA binding domain, in particular where the donor DNA includes the lac opera